Dianthus Therapeutics Inc. (DNTH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Dianthus Therapeutics Inc. stock (DNTH) is currently trading at $78.55. Dianthus Therapeutics Inc. PS ratio (Price-to-Sales) is 1650.80. Analyst consensus price target for DNTH is $127.75. WallStSmart rates DNTH as Sell.
- DNTH PE ratio analysis and historical PE chart
- DNTH PS ratio (Price-to-Sales) history and trend
- DNTH intrinsic value — DCF, Graham Number, EPV models
- DNTH stock price prediction 2025 2026 2027 2028 2029 2030
- DNTH fair value vs current price
- DNTH insider transactions and insider buying
- Is DNTH undervalued or overvalued?
- Dianthus Therapeutics Inc. financial analysis — revenue, earnings, cash flow
- DNTH Piotroski F-Score and Altman Z-Score
- DNTH analyst price target and Smart Rating
Dianthus Therapeutics Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Dianthus Therapeutics Inc. (DNTH) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Dianthus Therapeutics Inc. (DNTH) Key Strengths (2)
100.60% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Dianthus Therapeutics Inc. (DNTH) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -78.60%, a shrinking business
Very expensive at 1650.8x annual revenue
Very expensive at 6.2x book value
Supporting Valuation Data
Dianthus Therapeutics Inc. (DNTH) Detailed Analysis Report
Overall Assessment
This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 8.5/10) while 5 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (1650.80), Price/Book (6.16) suggest expensive pricing. Growth concerns include Revenue Growth at -78.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -38.40%, Operating Margin at -24486.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -38.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -78.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DNTH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DNTH's Price-to-Sales ratio of 1650.80x trades 280% above its historical average of 434.39x (92th percentile), historically expensive. The current valuation is 1% below its historical high of 1675x set in Mar 2026, and 2257% above its historical low of 70.05x in Dec 2023. Over the past 12 months, the PS ratio has expanded from ~138.6x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Dianthus Therapeutics Inc. (DNTH) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Dianthus Therapeutics Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 2M with 79% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 2942% of revenue (60M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 79% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -47M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Dianthus Therapeutics Inc..
Bottom Line
Dianthus Therapeutics Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Dianthus Therapeutics Inc.(DNTH)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.